School of Pharmacy, Shenyang Pharmaceutical University Shenyang, Liaoning Province 110016, People's Republic of China.
J Pharm Sci. 2012 Mar;101(3):1040-9. doi: 10.1002/jps.22813. Epub 2011 Nov 18.
The objective of this study was to propose novel surface-modified nanostructured lipid carriers with partially deacetylated water-soluble chitosan (NLC-PDSC) as an efficient ocular delivery system to improve its transcorneal penetration and precorneal retention. PDSC with a deacetylation degree of around 50% was synthesized using an improved method. NLC loaded with flurbiprofen (FB) were prepared by melt emulsification method. They presented spherical morphology under both transmission electron microscope and scanning electron microscope. After coating with 0.15% (w/v) PDSC solution, the NLC showed a core-shell structure and a reversed zeta potential. The enhanced transcorneal penetration of the coated NLC was evaluated using isolated rabbit corneas, with significantly increased apparent permeability coefficient being 1.40- and 1.75-fold of the NLC and FB phosphate solution (FB-sol; p < 0.05), respectively. Precorneal retention assessed by gamma scintigraphy in vivo showed that the area under the remaining activity-time curve of the PDSC-coated formulation was 1.3-fold of the NLC and 2.4-fold of FB-sol. Moreover, in vivo ocular tolerance study indicated that there was no difference in irritation between the coated and noncoated NLC. In conclusion, novel NLC demonstrate high potential for ocular drug delivery.
本研究旨在提出一种新型的经部分脱乙酰化水溶性壳聚糖(NLC-PDSC)表面修饰的纳米结构脂质载体,作为一种有效的眼部给药系统,以提高其角膜透过性和角膜前滞留性。采用改良方法合成脱乙酰度约为 50%的 PDSC。采用熔融乳化法制备负载氟比洛芬(FB)的 NLC。透射电子显微镜和扫描电子显微镜下均呈现为球形形态。用 0.15%(w/v)PDSC 溶液包覆后,NLC 呈现核壳结构和反转的zeta 电位。采用离体兔角膜评估包衣 NLC 的增强角膜透过性,其表观渗透系数分别显著增加 1.40 倍和 1.75 倍,与 NLC 和 FB 磷酸盐溶液(FB-sol;p<0.05)相比。体内γ闪烁法评估角膜前滞留性显示,包衣制剂的剩余活性-时间曲线下面积分别是 NLC 的 1.3 倍和 FB-sol 的 2.4 倍。此外,体内眼耐受性研究表明,包衣和非包衣 NLC 之间的刺激性没有差异。综上所述,新型 NLC 具有很大的眼部药物传递潜力。
Colloids Surf B Biointerfaces. 2016-3-22
Int J Nanomedicine. 2014-9-11
Front Chem. 2022-4-13
Int J Nanomedicine. 2021
Pharmaceutics. 2020-3-23
Adv Drug Deliv Rev. 2017-4-6
Int J Nanomedicine. 2014-9-11